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Abstract
Background: The wide offer of information on pharmaceuticals does not often fulfill physicians’ needs: problems of
relevance, access, quality and applicability are widely recognized, and doctors often rely on their own experience and
expert opinions rather than on available evidence. A quali-quantitative research was carried out in Italy to provide an
overview on information seeking behavior and information needs of doctors, in particular of infectious disease specialists,
and to suggest an action plan for improving relevance, quality and usability of scientific information.
Methods: We did a quantitative survey and three focus groups. Two hundred infectious disease specialists answered a
24-item questionnaire aimed at investigating features of scientific information they receive and their ratings about its
completeness, quality and usability. Subsequent focus groups, each involving eight specialists, investigated their opinions
on information sources and materials, and their suggestions on how these could better support their information needs.
Results: The quantitative survey indicated doctors’ appreciation of traditional channels (especially drug representatives)
and information materials (brochures), but also their attitude to autonomous search of information and their wish to
have more digital channels available. Focus groups provided more depth and, not surprisingly, revealed that physicians
consider critical to get complete, comparative and specific information quickly, but also that they would like to discuss
their doubts with expert colleagues. Quite strikingly, limited concerns were expressed on information validity, potential
biases and conflicts of interests, as scientific validity seems to be related to the perceived authoritativeness of
information sources rather than to the availability of a transparent evaluation framework.
Although this research investigated views of infectious disease specialists, we believe that their opinions and perceived
needs should not substantially differ from those of other clinicians, either in primary or in secondary care.
Conclusions: In participants’ view, the ideal information framework should provide quick and tailored answers
through available evidence and favor the exchange of information between practitioners and trusted experts.
The general consensus existing within the scientific and medical community on the need for integrating
available evidence and experience is confirmed, although the issues of information validity and conflicts of
interests seem definitely overlooked.
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This definition has been used a couple of decades ago
to qualify a situation health professionals often face:
loads of information from clinical studies, reviews,
guidelines made available through journals, websites,
meetings, etc. but not matching with access to valid,
relevant and eventually useful information when it is
needed [1, 2]. In two decades this situation has not
substantially changed: the information flow is even
growing, considering the ease of diffusion of digital
sources and their increasing popularity among physicians,
[3] so that in a recent editorial from the New York Times
physicians are attributed a “Stendhal syndrome”, such as
the French writer who felt overwhelmed by the pieces of
art surrounding him when he visited Florence [4].
However, unlike the relevance (and beauty) of Florentinian
paintings and sculptures, information materials targeted at
practitioners less frequently offer relevant and also intelli-
gible, practical and unbiased information, free from
conflicts of interests (CoI), on the effectiveness and safety
of drugs and other health care interventions that can be
usefully transferred to clinical practice [5, 6]. The
evidence-based medicine (EBM) movement advocated the
integration of individual clinical expertise with the best
available external clinical evidence from systematic
research [7]. However, difficulties in accessing and evaluat-
ing such evidence and limits in its application to individ-
ual patients [8] may cause over-reliance on expertise,
either as own experience or as enlightenment from
“experts”, [9] and on information brought directly or in-
directly by drug companies; the latter often represents
physicians’ main information source but inevitably reflects
interests of drug producers, [10] often being associated
with higher prescribing frequency and costs or lower pre-
scribing quality [11].
The gap between doctors’ information needs and ac-
cess to valid and relevant information does not seem a
fully exploited field of research. Specifically, there is lim-
ited research on doctors’ opinions about pros and cons
of different information sources, about how “old” chan-
nels (like pharmaceutical sales representatives – PSR -
and seminars) and materials (like scientific papers and
flyers) can be integrated by “new” digital channels (like
websites, tablet apps, e-mail alerts, etc.) to provide
physicians with relevant information and fill the know-
ledge gaps. In this regard opinions of hospital specialists
may be of particular relevance, considering their strong
request of information of high quality, often under time
pressure. The area of infectious diseases is of specific
interest, as in the last 15–20 years it witnessed a sharp
improvement in effectiveness of therapies, in particular
in the HIV area, but also potential concerns about their
high costs and consequently their sustainability for
health systems: for these reasons, physicians in this
clinical area may provide relevant insights about the
added value of drug information sources.
This quali-quantitative research explored opinions and
suggestions of infectious disease specialists to provide an
overview of information seeking behavior and informa-
tion needs of doctors, to suggest an action plan to im-
prove quality, relevance and usability of information on
drugs, the latter representing a key “equipment” for both
secondary and primary care physicians.
Methods
The research has been supervised by an Advisory
Committee and has been carried out by Doxa Institute,
an opinion research company, Italian branch of Gallup
International Association. It consisted of two parts: a
quantitative survey and a qualitative analysis by means
of three focus groups.
a) Quantitative survey. In September 2014, two
hundred infectious disease specialists expert in HIV
therapies were involved through Computer Assisted
Telephone Interview (CATI) and asked to answer to
a 24-item pre-tested questionnaire (see Additional
file 1). This survey was aimed at describing: the type
and frequency of drug information they receive from
drug firms or that they independently seek; investi-
gating their preference (expressed through numeric
scales from 1 to 10) about specific channels and
features of scientific information they receive from
PSR, meetings/congresses, courses, e-mails/web calls
and from independent sources; asking their ratings
about the quality, completeness, usability and cred-
ibility of such information, about which methodo-
logical characteristics of the presented data may
affect the quality of information and about their
preference on traditional vs new digital information
sources; and finally describe their unmet needs. The
questionnaire was pre-tested on ten physicians to as-
sess content validity and comprehensibility. The final
sample was randomly selected through an automatic
system of management of phone interviews, to allow
for a balanced distribution of respondents coming
from four geographic areas of Italy (north-west,
north-east, centre, south and islands). The sampling
frame came from a list of about 1000 physicians,
whose names were collected by Doxa, working in
infectious diseases hospital wards within the Italian
NHS or in NHS accredited hospitals, specialized in
providing care to HIV patients. A 95 % confidence
interval of ± 6,2 % was associated with the sample
size chosen. Data check and descriptive statistics
were performed using SAS® and DIANA® statistical
software, respectively.
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b) Qualitative research. Three focus-groups were run in
March 2015 in different cities (Milan, Rome and
Naples) and geographical areas, each involving eight
infectious disease specialists - expert in HIV therapies
- to discuss more in depth their information needs in
the context of clinical practice, their experience with
different information channels, and their suggestions
on how they could be better supported in order to
meet their information needs. Doctors were asked to
share their opinions on drug information starting
from their view of the current model, exploring their
information needs and stimulating their suggestions
on optimal ways to address these needs. Specifically,
the moderator progressively elicited their opinions on
information sources and materials as for their reliabil-
ity (scientific validity and transparency), completeness
(if there are gaps in information they would need and
if they are presented with all the available information)
and usability (easy access, rapid uptake and imple-
mentability). Additional file 2 provides details about
the structure of the focus groups and their contents,
addressed through specific questions. Participants
were randomly selected out of the same list men-
tioned above as for the survey methodology; criteria
were adopted to avoid that more than two of them
worked in the same hospital. None of the selected
physicians had participated to the quantitative survey.
Participants were not reimbursed for their time, but
provided with petrol coupons so that there were not
at a financial loss to attend the focus groups in person.
Focus groups were led by an expert moderator. Partic-
ipants’ answers were analyzed using content analysis,
by creating sub-categories and verifying the associ-
ation between the formulated hypotheses and con-
tents emerging from the focus groups. Quotes of
specific phrases stated by participants have been re-
ported (in italics); each participant was given an
unique ID code, assigned consecutively in each of the
three focus groups (ID 1 to 8, 9 to 16 and 17 to 24), to
allow assessing the spread of participant opinions.
Results
a) Quantitative survey
To obtain a geographically balanced sample of 200
respondents, 364 physicians had been contacted; 146
(40,1 %) declined to participate and 18 (4,9 %) did
not comply with the sampling criteria. Respondents
were mostly males (71 %), well experienced
professionals (only 17 % had less than 15 years of
professional experience) mostly assisting more than
300 patients a year (Table 1). In the previous
4 months almost all of them (98 %) received
information from PSR, on average a couple of
times a week; more than one-third also got in
contact with PSR through phone or web calls.
Sixty-five percent said they had participated to
sponsored meetings/congresses.
Generally speaking, PSR were the most appreciated
channel of information (average score of 8.5 out of 10)
followed by sponsored meetings/congresses (7.8/10).
Web calls (7.4/10) and especially phone calls (6.5/10)
were quite less appreciated, indicating doctors’
preference for information received through contacts
face-to face (Table 2). More specifically, PSR were the
most appreciated channels in terms of quality, cred-
ibility, completeness and usability (score 8.5 or 8.6/10)
although responses show little discrimination among
different channels, including those independent from
drug industry (Table 3). Opinions about transparency
and awareness of CoI followed the same pattern, and
PSR were regarded as the most transparent channel
(score: 8/10). As for qualifying contents presented by
PSR, respondents also showed little discrimination
among specific characteristics (like availability of RCTs
or systematic reviews, or use of absolute risk differ-
ences, or detailed information about patient character-
istics, etc.) and their perceived importance (Table 4).
As for scientific and/or promotional materials, most
respondents (89 %) received brochures from PSR,
although two-thirds also got paper information
available through websites and 29 % got kit of slides
or multimedia files. Overall, materials received were
mostly (75 %) in traditional (paper) format. Brochures
were the preferred ones (by 38 % of respondents)
followed by information available through websites
(20 %). Although opinions about traditional materials
and channels of information were quite positive, the
possibility of “digital” innovation (for example, receiv-
ing more information through the internet or digital
apps) was regarded favorably and 70 % would have
preferred digital channels, if available.
Overall, 84 % of respondents said they are satisfied
with information received (no unmet needs) and just
8 % said they would like more information on a
regular basis, but 71 % declared that they often or
always search information autonomously, especially
through the web and through scientific literature
(for 42 and 20 % the preferred sources, respectively).
b) Qualitative research
We report qualitative findings highlighting participants’
quotes in italics, associated with participants’ ID
codes (see also Table 5).
Pharmaceutical sales representatives and sponsored
sources
Positive opinions about PSR were confirmed. Flexibility
in setting meeting times and helpfulness in providing
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specific information “on demand” look as the main rea-
sons for such appreciation: “… when I ask for informa-
tion, PSR bring it to me the day after” “I like information
targeting specific needs … personalized” [participant ID
(P) 20]. In this specialist setting, respondents considered
PSR well prepared and able to put the information critic-
ally in context (“… they compare their drug to other ones,
bringing bibliography to support it” [P 1]). Transparency
of PSR goals was also considered very favorably: the
objectives of PSR and in general of the pharmaceutical
industry are explicit and knowing agenda and CoI of
information providers was regarded as a very important
feature (“… you know which side they are on and they
are honest in admitting that” [P10]). For this reason, also
sponsored symposia were deemed transparent and there-
fore not problematic (“It is clear who is behind them …
knowing it, we don’t have any problem” [P2]); usefulness
of symposia lies in the possibility of integrating different
points of view, also with the contribution of specialists
in different areas (“… for example, you can talk with
urologists to see how they approach infectious diseases in
urology” [P11]), although time required to participate
was considered an important limit (“… you can only
choose few events a year … depending on the time you
can put on them” [P12]). Activities sponsored by founda-
tions associated to drug companies were instead per-
ceived as “… more problematic, as their goals are not
transparent” [P15]. They were perceived as having a
potentially relevant role though, as “…arbiters between
pharmaceutical companies” [P13], “… setting the field for
objective, comparative assessments” [P14] “… providing
trustworthy information … being providers of culture”
[P22]; in this regard, they should not be related to
(financed by) one specific company, so that their
neutrality would be assured. CME courses, providing
Table 1 Characteristics of survey respondents (n = 200)
Geographical area Percent
•North west 27 %




• male 71 %
• female 29 %
Age
• ≤35 14 %
• between 35 and 45 13 %
• between 46 and 54 37 %
• >55 49 %
Professional experience
• ≤15 years 17 %
• between 16 and 20 years 21 %
• between 21 and 25 years 26 %
• >25 years 36 %
Assisted patients/year
• ≤100 16 %
• between 101 and 300 32 %
• >300 52 %
Table 2 Respondents’ scores on importance of information
channels (scale: 1–10; n = 200)















E-mail from journal 7.3 59 %
Phone calls from pharmaceutical
sales representative
6.5 30 %
Table 3 Respondents’ average scores on specific attributes of
information channels (scale: 1–10; n = 200)
Quality Credibility Completeness Usability
Pharmaceutical sales
representatives
8.6 8.5 8.5 8.5
Sponsored meetings -
congresses
8.3 8.2 8.2 8.1
Sponsored CME courses 8.2 8.2 8.1 8.1
Information independent
from drug industry
8.3 8.3 8.3 8.3
Table 4 Respondents’ scores on importance of specific elements
in information brought by pharmaceutical sales representatives
(scale: 1–10; n = 200)
Average score % scoring at
least 8/10
Availability of RCTs vs placebo 8.1 81 %
Use of absolute risk differences 8.0 79 %






Availability of systematic reviews 7.9 75 %
Availability of RCTs not sponsored
by drug companies
7.9 74 %
Indication of the added value
of drugs under study
7.9 71 %
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credits for professional update, often organized by
pharmaceutical companies, were perceived as the least
useful information channel (“… a lost occasion to get
relevant updates” [P8] “… completely useless … just
window-dressing … nobody checks if their contents are
adequate” [P3] “… we are just forced to participate to get
professional credits” [P10]).
Other information channels
As for channels not directly associated with pharmaceut-
ical companies, scientific societies were highly regarded
as they “… promote the scientific debate” [P6] “… using
authoritative sources, like world-famous opinion leaders
… big shots, who have great experience and have done
pivotal studies” [P8] “… when they talk, we just listen”
[P24]. Reliability of scientific journals (in particular of
those perceived as the most relevant ones) was highly
trusted too, since information is peer-reviewed (“…drugs
can be evaluated by researchers outside the sponsor
company” [P19]) and their online availability was seen as
a great advantage, allowing relatively easy searches of
different articles on the subject of interest and providing
a wide array of information on drug effectiveness and
safety (“… they are easy to search, using the right
keywords” [P14]). In this regard, internet in general was
considered as a wide and potentially relevant reservoir
of information (“… you can find everything you need …
just in time” [P14] “… have an overview” [P12] “… on
new drugs, drug interaction, safety” [P14]) but attention
is needed in selecting trustworthy information (“… there
is a risk of finding false information” [P21] “… you must
be careful” [P12, P21]). Lastly, guidelines (mostly those
developed by international panels) were considered
potentially useful for presenting a wide array of informa-
tion (“… they may not tell you the right solution for a
specific patient, but can help make your way” [P12] “…
and tailor one” [P21]), although they often refer to
populations “different from your own patients”, [P13]
may reflect the context of the country where they have
been written (“… in different countries they say different
things” [P19]) and are time consuming (“.. you cannot
read them in 1 min” [P12] “… they are huge” [P2]). On
the other hand, expert opinion and word of mouth
among colleagues (“… people with field experience” [P14]
“… with knowledge that you can’t find anywhere” [P22])
was pointed as an extremely important information
channel (“… information-sharing is really enriching”
[P10] “… it creates synergy” [P11] “… it is quick” [P4] “…
maybe directly at bedside” [P23] “… it refers to real
situations, unlike statistics in congresses” [P4]).
Table 5 Some quotes from focus groups on participants’ opinions about key features of drug information
Feature Quotes
Reliability “… information is reliable when it is transmitted by an authoritative source …”
“… world-famous opinion leaders … big shots, who have great experience and have done pivotal studies … when they talk,
we just listen …”
(in scientific research) “… the presence of authoritative and independent researchers is important …”
(in scientific journals) “…drugs can be evaluated by researchers outside the sponsor company …”
“… if the goal is improving patient care I trust it … I don’t if we talk about piddling …
Completeness “… it’s necessary to look at everything … let’s not just look at positive data … every drug has weaknesses and knowing
about them would bring added value to info …”
“ … comparative information to understand which drug is better for one patient and which for another one …”
“… if you don’t relate information to everyday practice, what is the use of it?…”
Usability “… easily accessible, through the web … in Pubmed … possibly free of charge …”
“… not too detailed … or pompous … it should be strict to the point … providing hints that I can deepen on my own …”
“… when I ask for information, drug reps bring it to me the day after …”
“… I like information targeting specific needs … personalized …”
(guidelines refer to populations) “different from your own patients … in different countries they say different things … you
cannot read them in one minute … they are huge …”
Exchange “… I would like talking with colleagues … they may have more experience with specific types of patients … sometimes I
don’t know how to manage them… I’d like getting help to choose the right drug for each patient …”
“… people with field experience … with knowledge that you can’t find anywhere …”
“… information-sharing is really enriching … it creates synergy … it is quick, maybe directly at bedside … it refers
to real situations, unlike statistics in congresses …”
“… let’s talk about real cases … there is a wide array of patients … they are different from theory … we also cure immigrants …”
Transparency –
conflicts of interest
(drug reps) “… you know which side they are on and they are honest in admitting that …”
(sponsored symposia) “… it is clear who is behind them … knowing it, we don’t have any problem …”
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Qualifying characteristics of scientific information
In participants’ view, reliability of information especially
depends on the presumptive authoritativeness of the
source (“… information is reliable when it is transmitted
by an authoritative source”) [P16] and of researchers
submitting it (“… the presence of authoritative and
independent researchers is important” [P14]) rather than
on critical assessment of evidence; other than that,
reliability was associated with relevance to patient care
(“… if the goal is improving patient care I trust it … I
don’t if we talk about futile arguments” [P17]) and to
items like study sample size (“… sometimes they don’t
even tell you about that” [P5]) and comparison groups
(“… knowing the difference vs alternative treatments
would be very useful” [P7]).
Completeness of information was associated with the
availability of negative and not just positive data (“… it’s
necessary to look at everything … let’s not just look at
positive data” [P3] “… every drug has weaknesses and
knowing about them would bring added value to info”
[P8]), of data on side effects and drug interactions, on
comparative data to assess “… which drug is better for
one patient and which for another one” [P8] and of
post-marketing data so that effectiveness in everyday
practice could be assessed (“… if you don’t relate infor-
mation to everyday practice, what is the use of it?” [P5]).
As for usability, information should be “easily accessible
… in Pubmed” [P18] “… through the web, possibly free of
charge” [P9] and “… not too detailed … or pompous … it
should be strict to the point … providing hints that I can
deepen on my own …” [P6].
How physicians’ information needs may be addressed
According to participants, a community of physicians
coordinated by trusted opinion leaders and connected
through the web could be the ideal answer to physicians’
information needs (“… I would like talking with
colleagues” [P10] “… they may have more experience
with specific types of patients” [P9] “… sometimes I don’t
know how to manage them” [P19] “… I’d like getting help
to choose the right drug for each patient” [P10]).
Colleagues could share their case reports and their
everyday experience (“… let’s talk about real cases …
there is a wide array of patients … they are different from
theory … we also cure immigrants” [P11]), which could
be integrated by easily accessible evidence-based infor-
mation from bibliographic databases and authoritative
scientific journals.
Discussion
This research offers a number of important elements to
enlighten the debate on doctors’ information needs and
information seeking behavior, integrating the results of a
quantitative survey with findings from three focus
groups, and gathering participants’ suggestions on how
to improve access to, perceived quality, relevance and
usability of, scientific information. In particular, focus
groups enriched findings from the quantitative survey,
allowing for better discrimination of perceived reliability
and usefulness of different information sources, for
in-depth analysis of physicians’ information needs and
for defining their suggestions to meet these needs. Even
considering the specificity of investigating opinions of
specialists in infectious diseases and HIV therapies in
Italy, which is the main limit of this research, we believe
that it could bring relevant contents to the debate on
drug information needs in general as drugs are the most
important “equipment” for all clinicians - in either
secondary or primary care - and all of them share the
need to keep pace with drug related research in spite of
hurdles like time constraints, pressure from drug
companies and also from patients and health managers.
The quantitative survey showed that PSR are consid-
ered as valuable information providers, mainly because
they are always available to supply information with a
flexible schedule and also “on demand”. We cannot say
whether such views were swayed by other positive rein-
forcements offered by PSR in addition to their support
and time flexibility. However, appreciation of “traditional”
channels (PSR) and info materials (brochures) seemed to
be partly contradicted by doctors’ positive attitude to
autonomous search of information, and by their wish to
have more digital channels available to build an enhanced
information framework; anyway, the overall picture emer-
ging from the survey suggests that respondents were quite
satisfied with the information they receive. Focus groups
allowed for in-depth analysis and integration of these
initial findings, showing a more articulated picture and a
deeper understanding of limits that currently available in-
formation may have. In particular, participants’ opinions
about strength and weaknesses of different information
sources, channels and materials clearly revealed two
general features that an information framework should
have in order to meet with doctors’ perceived needs: on
one side, physicians would like to be able to get – from
dedicated professionals like PSR and also autonomously –
complete, comparative (vs alternative treatments) and
practical information quickly, targeting specific needs they
would have in specific clinical circumstances, so that it
can be easily used in everyday clinical practice; on the
other side they would need to discuss their doubts with
expert colleagues and get support from their experience.
Therefore information focusing on specific needs should
be “quick and easy” to access through PSR, internet and
digital supports but should be also, and especially, shareable
among practitioners and mediated by expert opinion: in
other words, an evolution would be needed towards a more
integrated use of the web for quick and targeted answers to
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clinical questions, combining the power of bibliographic
and clinical databases on one side and clinical experience
and expert opinions on the other side.
These findings are not completely new. Looking at
the available literature, even though scientific articles
from a few years ago may not fully reflect the current
situation with the evolution of information frame-
works, there are two main elements that characterize
the information needs of doctors and their seeking
behavior. First, their demand for quick answers
associated to time constraints; [12–14] and second,
their reliance on experience from expert colleagues,
who can (quickly) provide hints overcoming the diffi-
culty to apply information about “average” patients to
their own clinical encounters [2, 12, 15].
It is worthy of note that participants to our research
were primarily concerned with the object of the
information they want (targeted to specific patient needs
- often not covered in scientific literature, which is
mainly centered on “average” patients) and on the infor-
mation framework that should provide it quickly (hyper-
connected, with both expert colleagues and databases).
Limited concerns were expressed on more specific char-
acteristics of information, like its validity, potential
biases and actual “evidence-base”: the need for informa-
tion materials based on a reproducible analysis of the
available evidence (therefore, based on a systematic
methodology) was not focused on, and the threats due
to non-publication of negative studies (publication bias)
were generically dealt with as need to have also negative
and not just positive data available. Limited concerns
were also expressed about the need for information in-
dependent from vested interests, although independence
– together with authoritativeness – of researchers has
been cited as desirable. In this regard, knowing who
produces the information was generally regarded as a
fundamental element to qualify it as potentially useful,
regardless of the presence of CoI. For example, partici-
pants did not show concerns about possible CoI and
hidden biases associated to sponsored studies: they were
confident that the filter operated by peer-review in
scientific journals helps select valid research and that
their own evaluation, together with their own and their
colleagues’ personal experience, could help identify
scientifically valid information as well as its applicability.
Scientific validity seems to be assured by the perceived
authoritativeness of information sources rather than the
availability of an explicit and transparent evaluation
framework, which is not asked for. Journal names, or
names of experts who share their opinion, or names of
scientific societies seem more important than an
evidence-based assessment of the contents, that infor-
mation materials generally do not provide in a plain and
intelligible way and which would require time and skills
that doctors generally do not have [16, 17]. No concerns
about CoI of scientific journals [18] had been expressed
either.
If we consider qualitative limits in the current offer of
information to physicians, lack of EBM training in
medical schools and time constraints, relying on the
perceived authoritativeness of experts, local opinion
leaders, [19] journals or societies may be an expected
outcome and may often be a necessary shortcut to over-
come difficulties in assessing the available evidence and
using it in everyday practice. Risk of slipping from evi-
dence to “eminence” based medicine – as self-referential
assessment of health care interventions has been facetiously
defined [20] - is concrete. More efforts are needed to pro-
vide doctors with more informative, useful and, at the same
time, scientifically valid materials (either on web or on
paper), based on systematic analyses of the available evi-
dence [21] and synthesized through easy-to-read formats.
These should ideally show a clear description of the charac-
teristics of study populations, discuss results using absolute
risk differences, evaluate possible study biases and highlight
what the information does add in defining the place in
therapy of drugs comparing to what is known about the
therapeutic alternatives [5, 22]. Of course, web materials
would allow different and additional layers of information
through the use of hypertexts, and enhanced search engines
would help accelerate the search for tailored answers.
Such ideal framework for evidence-based informa-
tion would not be at odds with experience and expert
opinions mediating its translation in clinical practice:
evidence itself, if deployed by a thorough evaluation
of the clinical context where it would be applied, is
perceived as an academic exercise and can be of little
use. The need for integrating a transparent assess-
ment of evidence with experience is what the
evidence-based movement itself has always advocated
as David Sackett, considered one of the fathers of
EBM, clearly wrote in a landmark 1996 editorial: “The
practice of evidence based medicine means integrating
individual clinical expertise with the best available
external clinical evidence from systematic research”
[7]. In keeping with this principle, clinical practice
guidelines are (or should be) developed through a
systematic assessment of the available evidence [23]
made by multidisciplinary groups of experts [24].
Such integration of evidence and experience, taking
the collaborative nature of medical work into consid-
eration, [25] is quite different from that “eminence-
based” medicine, based on self-referential attitudes
that many opinion leaders often show: while providing
practical answers and hints to their colleagues, the so
called experts would need to support their opinions with a
transparent assessment of the available evidence, and
show that they do not have potential CoI that may drive
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their opinions. This principle has been advocated for the
development of clinical guidelines too, asking for clear dis-
closure of CoI and exclusion of experts with relevant and
non-resolvable CoI [24].
Conclusion
This research suggests that institutional subjects who
want to provide information to physicians should
answer to a big challenge: providing quick, tailored
and patient-centered answers through a transparent
framework of available, comparative evidence, assessed
for its validity and referred to the clinical context
where it would be used, mediated by trusted experts
with no relevant CoI who could help put the evidence
in context; and favoring the exchange of information
between practitioners. A big, big challenge, whose
complexity had been already highlighted 20 years ago
in a landmark paper by Richard Smith, where he
weighted the “evergreen” role of experience from col-
leagues: [2]“… Probably there will be no single tool
but a family of tools, and I suspect that, whatever
sophisticated tools may be developed, the major source
of information will remain colleagues”. Transparency
of information (in its selection and assessment) and
of experts’ CoI will be essential elements to consider
for anybody who wants to compete on this field. As
for specific key features, the development of
evidence-based but uncomplicated information tools
is already in a quite advanced stage in some countries
like for example UK, Germany, Canada and the US.
However, the development of relevant policies on CoI
seems to be a general problem [26, 27]. Not to forget
that patient-centered answers will require more pa-
tient-centered research, [28, 29] as our focus groups
clearly indicated: participation of patients’ representatives
in multidisciplinary panels defining research priorities [30]
is an upstream requisite, so that information is not built
on insubstantial grounds.
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